N/A N=22 Proton Radiotherapy for Upper Gastrointestinal Malignancies
Gastrointestinal Cancer
Primary: Serious Adverse Events — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=15 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Phase 2 N=51 HIPEC for Peritoneal Carcinomatosis
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
N/A N=24 Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo
Gastrointestinal Stromal Tumors
Primary: Number of Patients Who Survived — 5 Participants
Phase 2 N=63 Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Rate of Disease Progression at 2 Years — 13.8 percentage of participants
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
N/A N=492 Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST)
Gastro Intestinal Stromal Tumor
Primary: Time to Next Treatment (TNT) — 26.7 months
Phase 1 N=18 Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies
Peritoneal Surface Malignancy
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants
Phase 1 N=23 Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
Phase 2 N=50 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Fallopian Tube Cancer · Ovarian Sarcoma · Ovarian Stromal Cancer
Primary: Acute Toxicity Rate — 6 percentage of participants
N/A N=350 Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Non-small Cell Lung Cancer · Small Cell Lung Cancer · Mesothelioma
Primary: Functional Assessment of Cancer Therapy (Quality of Life Measure) — 81.10; 77.70 units on a scale
Phase 2 N=19 Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
Gastrointestinal Cancer
Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months
Phase 3 N=30 Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis
Gastrointestinal Neoplasm
Primary: Progression Free Survival
Phase 1 N=33 Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
Gynecologic Tumors
Primary: Dose Limiting Toxicity (DLT) — 8; 23; 2 participants
Phase 2 N=38 Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
Gastrointestinal Neoplasms · Ovarian Neoplasms
Primary: Overall Response — 3 participants
N/A N=12 Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)
Cancer of the Cervix · Cervical Neoplasms
Primary: Maximum Tolerated Dose of Integrated Boost Radiation Therapy, Administered With IMRT Technique With Concurrent Chemotherapy (Cisplatin). — 70 Gray (Gy)
Phase 2 N=24 Gleevec Study for Patients With Ovarian Cancer
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 0; 0 participants
Phase 2 N=21 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Toxicity Rates of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy — 766 Events
Phase 2 N=18 Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
Phase 2 N=26 Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
Stomach Neoplasms · Esophageal Neoplasms
Primary: Overall Response Rate (ORR) — 39.1 percentage of participants
Phase 2 N=95 Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
Gastric Cancer · Stomach Cancer · Esophageal Cancer
Primary: Number of Patients With Dose Limiting Toxicities — 0; 0 Participants
Phase 1 N=20 TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma · GastroEsophageal Cancer
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants
Phase 2 N=20 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
Mixed Mullerian Tumors of the Uterus
Primary: Chemotherapy Completion Rate — 100 percentage of participants
Phase 2 N=83 A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.
Neoplasms
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 52.9; 53.1 percentage of participants
Phase 2 N=27 Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
Gastric Adenocarcinoma · Esophagogastric Junction · Gastric Cancer
Primary: Overall Survival (OS) — 11.96 Months
Phase 2 N=17 A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
Recurrent Gastric Cancer · Stage IV Gastric Cancer
Primary: Response Rate — 0 percentage of patients responding
Phase 2 N=39 FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Gastroesophageal Cancer · Gastric Cancer
Primary: Progression Free Survival — 7.8 months
Phase 1 N=3 FT516 and IL2 With Enoblituzumab for Ovarian Cancer
Ovarian Cancer · Fallopian Tube Adenocarcinoma · Primary Peritoneal Cavity Cancer
Primary: Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events — 0; 0; 0 Participants
Phase 2 N=98 S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
Esophageal Cancer
Primary: Pathological Complete Response — 26 participants
N/A N=20 Giving Information Systematically and Transparently in Lung and GI Cancer Phase 1
Critical Illness · Oncology · Communication
Primary: Acceptability of the Proposed Intervention According to a Structured Qualitative Survey of Caregivers — 9; 10; 1; 3 Participants